Treatment becoming increasingly segmented
Targeted therapies and various biomarkers (e.g., RAS, BRAF, MSI-H,dMMR) play an important role in the treatment of colorectal cancer. Treatment is becoming increasingly segmented by the side on which the tumor is located, BRAF status, and MSI-H or dMMR status. Immune checkpoint inhibitors targeting MSI-H / dMMR metastatic colorectal cancer are experiencing uptake and influencing current treatment algorithms. Therapies targeting specific biomarker-defined populations, such as BRAF-mutant metastatic colorectal, contribute to more-personalized treatment.